Alivus Life Sciences Ltd · NSE:ALIVUS
Alivus Life Sciences — Q3 FY23 Earnings Presentation
20 slides from Alivus Life Sciences's earnings presentation, Jan 27, 2023
Slide 1: Glenmark Life Sciences Investor Presentation cover letter
6 qlenmaRk LIFE SCIENCES Partnership Innovation. Passion. January 27, 2023 To, To, Dy. General Manager The Manager - Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai - 400
Slide 2: Investor Presentation Q3 & 9M FY23
Investor Presentation Q3 & 9M FY23
Slide 3: Financial Performance Review
Financial Performance Review
Slide 4: Q3 FY23 – Highlights
Q3 FY23 – Highlights “I am pleased to report that the Company has continued its upward trajectory to witness steady growth both on sequential as well as YoY basis on the back of a robust performance of Dr. Yasir Rawjee our external business. India, Europe and LATAM were the main catalysts for growth
Slide 5: Q3 & 9M FY23 Performance
Q3 & 9M FY23 Performance Sustaining a profitable growth trajectory despite cost & supply chain headwinds PAT Revenue EBITDA EBITDA PAT EPS (In ₹ Millions) (In ₹ Millions) (In ₹ Millions) PAT Margin (In ₹) EBITDA Margin 31.9% 30.2% 22.2% 21.0% 28.6% 19.8% 8.87 19.2% 19.4% 5,407 8.72 28.7% 8.65 28.1%
Slide 6: P&L Highlights – Q3 & 9M FY23
P&L Highlights – Q3 & 9M FY23 P a rticulars (In ₹ Millions) Q3 FY23 Q2 FY23 QoQ Q3 FY22 YoY 9M FY23 9M FY22 YoY Revenue from Operations 5,407 5,093 6.2% 5,225 3.5% 15,399 16,092 -4.3% Gross Profit 2,759 2,693 2.4% 2,653 4.0% 8,062 8,214 -1.9% Gross Profit (%) 51.0% 52.9% 50.8% 52.4% 51.0% Other Inco
Slide 7: Strong Returns Indicators
Strong Returns Indicators ROICE Fixed A ssets Turnover Wo rking Capital D ays 40% 202 173 176 178 35% 36% 3.3 3.4 152 31% 32% 2.9 2.8 2.7 98 99 117 104 89 116 152 120 116 128 FY19 FY20 FY21 FY22 9M FY23 FY19 FY20 FY21 FY22 9M FY23 -47.0 -48.0 -43.0 -53.0 -67.0 • ROICE is tracking at 32% – Higher cap
Slide 8: Financial Performance Track Record
Financial Performance Track Record Robust growth and profitability indicators over the years Revenue EBITDA PAT EPS (In ₹ Millions) (In ₹ Millions) (In ₹ Millions) (In ₹) EBITDA PAT EBITDA Margin PAT Margin 20.8% 20.4% 31.5% 31.4% 29.7% 19.7% 18.6% 35.6 CAGR 15.3% 30.6% 21,232 19.1% 4,187 32.6 6,308
Slide 9: Business Performance Review
Business Performance Review
Slide 10: Segment Performance – Generic & CDMO business
Segment Performance – Generic & CDMO business Generic A PI CDMO (Revenue In ₹ Millions) (Revenue In ₹ Millions ) 4,799 435 406 4,715 309 4,590 279 4,533 243 4,448 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 • Generic API revenues in Q3FY23 increased 5.9% • CDMO re
Slide 11: Segment Performance – GPL vs. External
Segment Performance – GPL vs. External External GPL GPL External (In ₹ Millions) (In ₹ Millions) % of Total Revenue % of Total Revenue 41.0% 74.0% 71.0% 36.0% 64.0% 66.0% 34.0% 59.0% 2,150 29.0% 3,755 3,814 1,855 26.0% 3,286 3,242 1,657 3,075 1,594 1,338 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Q3 FY
Slide 12: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix Market Mix Therapeutic Area Mix 18% 24% 27% 28% 25% 28% 29% 35% 35% 39% 6% 8% 4% 4% Others 8% 7% Emerging 7% 10% 5% Pain Management Markets 3% 15% 14% 18% 14% 12% Diabetes 82% 76% 73% 72% 75% CNS Regulated Markets CVS 43% 42% 40% 36% 37% Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY2
Slide 13: Company Overview
Company Overview LIFE SCIENCES
Slide 14: Global Footprint
Global Footprint • Filed 456 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia RO W 60+ 3 50+ 30+ 92 1 09 1 52 10+ 17 1 20+ 10+ 50+ 17 69 (Brazil) India – Mix of Regulated Number of Number of customers As of December 31
Slide 15: Quality-focused, compliant manufacturing & R&D infrastructure
Quality-focused, compliant manufacturing & R&D infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Capacity Last USFDA Mahape, Navi Mumbai Location Approvals (Dec-22) Inspection Date R&D for new product development and complex molecules USFDA, MHRA (UK), FIMEA (Finland)
Slide 16: R&D Capabilities
R&D Capabilities Cumulative Filing Status R&D Spend (In ₹ Millions) North Therapy Europe Japan Brazil Australia ROW Total America R&D Spend CVS 36 31 4 17 10 26 124 As % to Sales CNS 35 20 7 13 1 13 89 Diabetes 9 4 - 8 - 12 33 3.2% 2.7% 2.7% 2.6% Pain Management 1 2 - 4 1 8 16 Others 71 35 6 27 5 50
Slide 17: Strategy Going Forward
Strategy Going Forward A LIFE SCIENCES
Slide 18: Strategic Growth Levers
Strategic Growth Levers 1 Gx API Business New product launches Geographical expansion Focus on new markets becoming more regulated New Growth levers 2 Pursue 2nd source opportunities with top generic players Ramp up CDMO portfolio Expand into complex API platforms Iron compounds Onco
Slide 19: Future Capacity Expansion Plan
Future Capacity Expansion Plan Operational Expansion Type Division Location Current Capacity Status & Planned Capacity Timelines 240 KL capacity added in Nov Brownfield API Dahej 381.9 KL - 2022 Under Construction Brownfield Intermediate Ankleshwar 550.2 KL Q4 FY23 400 KL Brownfield Oncology Dahej -
Slide 20: Thank You
Thank You FOR FURTHER INFORMATION CONTACT Email: complianceofficer@glenmarklifesciences.com ERNST & YOUNG LLP – INVESTOR RELATIONS DIWAKAR PINGLE RAHUL THAKUR Email: Diwakar.Pingle@in.ey.com Email: rahul.thakur@in.ey.com Mobile: +91 98333 19957 CORPORATE OFFICE: REGISTERED OFFICE: T: 91 22 68297979